Skip to main content

Sturge-Weber Syndrome (SWS)

2
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Biocorp
BiocorpFrance - Issoire
1 program
1
QLS-101ophthalmic solution 1%Phase 21 trial
Active Trials
NCT04947124Completed3Est. Aug 2022
Qlaris Bio
Qlaris BioMA - Dedham
1 program
1
QLS-101ophthalmic solution 1%Phase 2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BiocorpQLS-101ophthalmic solution 1%

Clinical Trials (1)

Total enrollment: 3 patients across 1 trials

NCT04947124BiocorpQLS-101ophthalmic solution 1%

A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101

Start: Oct 2021Est. completion: Aug 20223 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.